Acne is the most common skin condition in the U.S., affecting up to 50 million Americans annually. Acne vulgaris treatment involves a lot more than just killing the bacteria that causes acne. It is a fact that the bacteria, Cutibacterium acnes, is the cause of most pimples. However, there are many other factors that can contribute to your acne problem. Improper skin care, hormonal changes and improper treatment can all make pimples worse.
The global acne vulgaris treatment market is witnessing several merger and acquisition activities. For instance, in 2017, L’Oréal signed an agreement with Valeant Pharmaceuticals International, Inc. to acquire its skin care brands portfolio which includes anti-acne brand AcneFree.
Request a FREE sample copy – Acne Vulgaris Treatment market report click here:
R&D of new products is expected to propel growth of the global acne vulgaris treatment market over the forecast period. For instance, in November 2017 Novan Inc. announced to conduct a clinical trial to assess the efficacy of its new anti-acne molecule.
Moreover, high prevalence of acne is also expected to propel growth of the global acne vulgaris treatment market over the forecast period. For instance, in 2015, 9.4% of the population worldwide was suffering from acne, according to a study published in the British Journal of Dermatology.
The global acne vulgaris treatment market is witnessing several merger and acquisition activities. For instance, Valeant Pharmaceuticals International, Inc. completed the sale of the Obagi Medical Products business to Haitong International Zhonghua Finance Acquisition Fund I, L.P.
Major players operating in the global acne vulgaris treatment market are focused on approval and launch of new products to expand their product portfolio. For instance, in August 2020, Cassiopea SpA received the U.S. Food and Drug Administration approval for Winlevi (clascoterone cream 1%), an acne drug with a new mechanism of action.
Request PDF Brochure with Latest Insights @
North America is expected to witness significant growth in the global acne vulgaris treatment market, owing to increasing expenditure on treatment of acne vulgaris. For instance, in 2013, over US$ 3 billion was spent for the treatment of acne vulgaris in the U.S., according to study by National Institute of Health.
Major players operating in the global acne vulgaris treatment market include, Allergan plc, Bayer AG, F. Hoffmann-La Roche AG, Galderma Inc., GlaxoSmithKline plc, Janssen Pharma Inc., Mylan, N.V., Novan Inc., Pfizer Inc., and Valeant Pharmaceutical International Inc.,
Major players operating in the global acne vulgaris treatment market are focused on launching new products to expand their product portfolio. For instance, in September 2020, Alembic Pharmaceuticals launched Adapalene Gel USP 0.3%, a topical retinoid for the treatment of acne vulgaris in patients 12 years and older. The product is equivalent to Differin Gel 0.3% (Galderma).
Reasons to Buy this Acne Vulgaris Treatment Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Acne Vulgaris Treatment market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Acne Vulgaris Treatment market
➡Leading company profiles reveal details of key Acne Vulgaris Treatment market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Acne Vulgaris Treatment market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
Buy This Complete Business Report With Flat USD 2000 Off @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Acne Vulgaris Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Acne Vulgaris Treatment Industry Impact
Chapter 2 Global Acne Vulgaris Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Acne Vulgaris Treatment (Volume and Value) by Type
2.3 Global Acne Vulgaris Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Acne Vulgaris Treatment Sales, Consumption, Export, Import by Regions
Chapter 5 North America Acne Vulgaris Treatment Market Analysis
Chapter 6 East Asia Acne Vulgaris Treatment Market Analysis
Chapter 7 Europe Acne Vulgaris Treatment Market Analysis
Chapter 8 South Asia Acne Vulgaris Treatment Market Analysis
Chapter 9 Southeast Asia Acne Vulgaris Treatment Market Analysis
Chapter 10 Middle East Acne Vulgaris Treatment Market Analysis
Chapter 11 Africa Acne Vulgaris Treatment Market Analysis
Chapter 12 Oceania Acne Vulgaris Treatment Market Analysis
Chapter 13 South America Acne Vulgaris Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Acne Vulgaris Treatment Business
Chapter 15 Global Acne Vulgaris Treatment Market Forecast (2021-2028)
Chapter 16 Conclusions
𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐃𝐞𝐭𝐚𝐢𝐥𝐬? 𝐓𝐚𝐥𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐀𝐧𝐚𝐥𝐲𝐬𝐭 @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1260
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027